search
Back to results

Dietary Sodium Intake and Blood Pressure in Living Kidney Donors (SPLID)

Primary Purpose

Hypertension, Living Kidney Donor, Dietary Sodium Intake

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dietary sodium
Sponsored by
University of California, Irvine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Living kidney donor, High blood pressure, Salt intake, Clinical trial

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Living kidney donors who underwent a living kidney donation at least 5 months ago but not more than 12 months
  • Age ≥18 years old
  • Agree to perform the procedure as per study protocol (Table 1)
  • Living kidney donors with an average sitting SBP <160 mmHg at 5-month post-donation measured by automatic office blood pressure (AOBP)
  • Able to sign informed consent
  • Able to attend all research visits
  • Woman using birth control methods other than hormonal contraception

Exclusion Criteria:

  • History of previous cardiovascular (CV) events including acute MI, HF, and stroke
  • Symptomatic heart failure within 5 months after living kidney donation or left ventricular ejection fraction (by any method) <35%
  • CV event or procedure or hospitalization for hypertensive-related disorders within 5 months after living kidney donation
  • Diagnosed with HTN or on antihypertensive medication(s) before living kidney donation
  • Patients who are supposed to take BP lowering medications for reasons other than BP control but do not take those medications or take them with in appropriate doses
  • Arm circumference is too small or large to allow accurate BP measurement with available 24-h ABPM machines.
  • An average standing SBP ≥160 mmHg at 5-month post-donation measured by automatic office blood pressure (AOBP)
  • Albuminuria that equals or is equivalent to 1 g per day by using spot urinary albumin per urine creatinine ratio (UACR) or 24-hour urinary albumin excretion rate by a 24-hour urine collection within 5 months post-donation
  • Advanced kidney function defined by estimated glomerular filtration rate (eGFR) by using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation22 of <20 ml/min/1.73m2 or requiring dialysis after living kidney donation
  • Drink coffee > two 8-ounce (237 mL) cup a day or equivalence
  • Drinks alcohol >3 drinks/day or >30 ml/day
  • Smoking cigarette ≥10 cigarettes/day
  • Take Nonsteroidal anti-inflammatory drugs (NSAIDS)
  • Use hormone replacement therapy or oral contraceptives
  • Pregnancy, currently trying to become pregnant
  • Using birth control pills
  • A medical condition likely to limit survival to less than 2 years
  • Any factors that are likely to limit adherence to interventions. For example,

    • Living kidney donors who cannot come to follow up regularly per study protocol to logistically collect data from enrolled participants.
    • Active alcohol or substance abuse within the last 5 months of living kidney donation
    • Plans to move outside the clinic catchment area in the next 4 months without the ability to transfer to come to follow up at SPLID study site.
    • Significant history of poor adherences with medications or attendance at clinic visits
    • Significant concerns about participation in the study from spouse, significant other, or family members
    • Lack of support from primary health care provider
    • Residence too far from the study clinic site such that transportation is a barrier including persons who require transportation assistance provided by the SPLID clinic funds for screening or randomization visits
    • Residence in a nursing home or an assisted living
    • Clinical dementia with or without treatment with medications and cognitively unable to follow the protocol
    • Other medical, psychiatric, or behavioral factors that may interfere with study participation or the ability to follow the intervention protocol
    • Inability to obtain informed consent from participant
    • Living in the same household as an already randomized SPLID participant

Sites / Locations

  • University of California Irvine Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

lowsodium

highsodium

Arm Description

Participants in this arm will be guided to have low dietary sodium intake of <2.3 g/day (<100 mmol/day) for 4 weeks.

Participants in this arm will be guided to have low dietary sodium intake of ≥4 - <6 g/day (≥174 - <261 mmo/day) for 4 weeks.

Outcomes

Primary Outcome Measures

Change in systolic and diastolic blood pressure from baseline to post-treatment between the two treatment groups
Change in systolic and diastolic blood pressure from baseline to post-treatment between the two treatment groups, adjusting for patients' demographic and clinical differences (age, gender, BMI, and comorbidities) between the two treatment groups

Secondary Outcome Measures

Hypertension
New-onset hypertension defined as systolic blood pressure >/= 130 or diastolic blood pressure >/=80 mmHg
Worsening kidney function
Increased estimated glomerular filtration rate (eGFR) >/= 25 ml/min/1.73 m2 or increased serum creatinine >/= 0.3 mg/dL
Worsening proteinuria
Increase in urinary albumin excretion rate (AER) ≥30 mg/day
Proteinuria
New-onset urinary albumin excretion rate (AER) ≥30 mg/day

Full Information

First Posted
September 3, 2021
Last Updated
November 30, 2022
Sponsor
University of California, Irvine
search

1. Study Identification

Unique Protocol Identification Number
NCT05041829
Brief Title
Dietary Sodium Intake and Blood Pressure in Living Kidney Donors
Acronym
SPLID
Official Title
Dietary Sodium Intake and Blood Pressure in Living Kidney Donors: A Pilot Single-Center Crossover Single-Blind Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 3, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Irvine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a pilot study to determine the feasibility of the study design and examine the main outcome whether low dietary sodium intake is superior to high dietary sodium intake in controlling blood pressure to be within the normotensive range in living kidney donors.
Detailed Description
This is a pilot study to determine the feasibility of the study design and examine the main outcome whether low dietary sodium intake <2.3 g/day (<100 mmol/day) is superior to high dietary sodium intake ≥4 - <6 g/day (≥174 - <261 mmo/day) in controlling blood pressure (BP) to be within normotensive range, lowering systolic and diastolic blood pressures (SBP and DBP) from the baseline blood pressures, and decreasing the risk of hypertension, worsening kidney function, and proteinuria in living kidney donors between 5 and 12 months after living kidney donation?.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Living Kidney Donor, Dietary Sodium Intake
Keywords
Living kidney donor, High blood pressure, Salt intake, Clinical trial

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
There are two 4-week experimental periods, each participant will received low and high sodium diet during one of the periods and the order of the amount of sodium diet will be determined by randomization.
Masking
Investigator
Masking Description
Investigator will be masked for assigned amount of dietary sodium intake of participants.
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
lowsodium
Arm Type
Experimental
Arm Description
Participants in this arm will be guided to have low dietary sodium intake of <2.3 g/day (<100 mmol/day) for 4 weeks.
Arm Title
highsodium
Arm Type
Active Comparator
Arm Description
Participants in this arm will be guided to have low dietary sodium intake of ≥4 - <6 g/day (≥174 - <261 mmo/day) for 4 weeks.
Intervention Type
Other
Intervention Name(s)
Dietary sodium
Intervention Description
Low sodium diet with sodium of <2.3 g/day (<100 mmol/day) and high sodium diet with sodium of ≥4 - <6 g/day (≥174 - <261 mmo/day)
Primary Outcome Measure Information:
Title
Change in systolic and diastolic blood pressure from baseline to post-treatment between the two treatment groups
Description
Change in systolic and diastolic blood pressure from baseline to post-treatment between the two treatment groups, adjusting for patients' demographic and clinical differences (age, gender, BMI, and comorbidities) between the two treatment groups
Time Frame
4 weeks after dietary intervention pre-crossover and 4 weeks after dietary intervention post-crossover
Secondary Outcome Measure Information:
Title
Hypertension
Description
New-onset hypertension defined as systolic blood pressure >/= 130 or diastolic blood pressure >/=80 mmHg
Time Frame
4 weeks after dietary intervention pre-crossover and 4 weeks after dietary intervention post-crossover
Title
Worsening kidney function
Description
Increased estimated glomerular filtration rate (eGFR) >/= 25 ml/min/1.73 m2 or increased serum creatinine >/= 0.3 mg/dL
Time Frame
4 weeks after dietary intervention pre-crossover and 4 weeks after dietary intervention post-crossover
Title
Worsening proteinuria
Description
Increase in urinary albumin excretion rate (AER) ≥30 mg/day
Time Frame
4 weeks after dietary intervention pre-crossover and 4 weeks after dietary intervention post-crossover
Title
Proteinuria
Description
New-onset urinary albumin excretion rate (AER) ≥30 mg/day
Time Frame
4 weeks after dietary intervention pre-crossover and 4 weeks after dietary intervention post-crossover

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Living kidney donors who underwent a living kidney donation at least 5 months ago but not more than 12 months Age ≥18 years old Agree to perform the procedure as per study protocol (Table 1) Living kidney donors with an average sitting SBP <160 mmHg at 5-month post-donation measured by automatic office blood pressure (AOBP) Able to sign informed consent Able to attend all research visits Woman using birth control methods other than hormonal contraception Exclusion Criteria: History of previous cardiovascular (CV) events including acute MI, HF, and stroke Symptomatic heart failure within 5 months after living kidney donation or left ventricular ejection fraction (by any method) <35% CV event or procedure or hospitalization for hypertensive-related disorders within 5 months after living kidney donation Diagnosed with HTN or on antihypertensive medication(s) before living kidney donation Patients who are supposed to take BP lowering medications for reasons other than BP control but do not take those medications or take them with in appropriate doses Arm circumference is too small or large to allow accurate BP measurement with available 24-h ABPM machines. An average standing SBP ≥160 mmHg at 5-month post-donation measured by automatic office blood pressure (AOBP) Albuminuria that equals or is equivalent to 1 g per day by using spot urinary albumin per urine creatinine ratio (UACR) or 24-hour urinary albumin excretion rate by a 24-hour urine collection within 5 months post-donation Advanced kidney function defined by estimated glomerular filtration rate (eGFR) by using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation22 of <20 ml/min/1.73m2 or requiring dialysis after living kidney donation Drink coffee > two 8-ounce (237 mL) cup a day or equivalence Drinks alcohol >3 drinks/day or >30 ml/day Smoking cigarette ≥10 cigarettes/day Take Nonsteroidal anti-inflammatory drugs (NSAIDS) Use hormone replacement therapy or oral contraceptives Pregnancy, currently trying to become pregnant Using birth control pills A medical condition likely to limit survival to less than 2 years Any factors that are likely to limit adherence to interventions. For example, Living kidney donors who cannot come to follow up regularly per study protocol to logistically collect data from enrolled participants. Active alcohol or substance abuse within the last 5 months of living kidney donation Plans to move outside the clinic catchment area in the next 4 months without the ability to transfer to come to follow up at SPLID study site. Significant history of poor adherences with medications or attendance at clinic visits Significant concerns about participation in the study from spouse, significant other, or family members Lack of support from primary health care provider Residence too far from the study clinic site such that transportation is a barrier including persons who require transportation assistance provided by the SPLID clinic funds for screening or randomization visits Residence in a nursing home or an assisted living Clinical dementia with or without treatment with medications and cognitively unable to follow the protocol Other medical, psychiatric, or behavioral factors that may interfere with study participation or the ability to follow the intervention protocol Inability to obtain informed consent from participant Living in the same household as an already randomized SPLID participant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ekamol Tantisattamo, MD, MPH
Phone
714-456-5142
Email
etantisa@hs.uci.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Tracy Nakata
Phone
714-456-7715
Email
nakatat@hs.uci.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ekamol Tantisattamo, MD, MPH
Organizational Affiliation
University of California, Irvine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ekamol Tantisattamo, MD, MPH
Phone
714-456-5142
Email
etantisa@hs.uci.edu
First Name & Middle Initial & Last Name & Degree
Tracy Nakata
Phone
714-456-7715
Email
nakatat@hs.uci.edu

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
23303884
Citation
Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586.
Results Reference
result
PubMed Identifier
7832839
Citation
Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med. 1994 Aug 11;331(6):365-76. doi: 10.1056/NEJM199408113310606. No abstract available.
Results Reference
result
PubMed Identifier
32734216
Citation
Subramanian L, Kirk R, Cuttitta T, Bryant N, Fox K, McCall M, Perry E, Swartz J, Restovic Y, Jeter A, Bernardo A, Robinson B, Perl J, Pisoni R, Perlman RL. Remote Management for Peritoneal Dialysis: A Qualitative Study of Patient, Care Partner, and Clinician Perceptions and Priorities in the United States and the United Kingdom. Kidney Med. 2019 Oct 17;1(6):354-365. doi: 10.1016/j.xkme.2019.07.014. eCollection 2019 Nov-Dec.
Results Reference
result
PubMed Identifier
15930096
Citation
Davis CL, Delmonico FL. Living-donor kidney transplantation: a review of the current practices for the live donor. J Am Soc Nephrol. 2005 Jul;16(7):2098-110. doi: 10.1681/ASN.2004100824. Epub 2005 Jun 1.
Results Reference
result
PubMed Identifier
31898417
Citation
Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Castro S, Foutz J, Wainright JL, Snyder JJ, Kasiske BL, Israni AK. OPTN/SRTR 2018 Annual Data Report: Kidney. Am J Transplant. 2020 Jan;20 Suppl s1:20-130. doi: 10.1111/ajt.15672.
Results Reference
result
PubMed Identifier
26700551
Citation
Lentine KL, Lam NN, Axelrod D, Schnitzler MA, Garg AX, Xiao H, Dzebisashvili N, Schold JD, Brennan DC, Randall H, King EA, Segev DL. Perioperative Complications After Living Kidney Donation: A National Study. Am J Transplant. 2016 Jun;16(6):1848-57. doi: 10.1111/ajt.13687. Epub 2016 Mar 10.
Results Reference
result
PubMed Identifier
30858158
Citation
Lentine KL, Lam NN, Segev DL. Risks of Living Kidney Donation: Current State of Knowledge on Outcomes Important to Donors. Clin J Am Soc Nephrol. 2019 Apr 5;14(4):597-608. doi: 10.2215/CJN.11220918. Epub 2019 Mar 11.
Results Reference
result
PubMed Identifier
31517140
Citation
Tantisattamo E, Dafoe DC, Reddy UG, Ichii H, Rhee CM, Streja E, Landman J, Kalantar-Zadeh K. Current Management of Patients With Acquired Solitary Kidney. Kidney Int Rep. 2019 Jul 11;4(9):1205-1218. doi: 10.1016/j.ekir.2019.07.001. eCollection 2019 Sep.
Results Reference
result
PubMed Identifier
31537534
Citation
Holscher CM, Haugen CE, Jackson KR, Garonzik Wang JM, Waldram MM, Bae S, Locke JE, Reed RD, Lentine KL, Gupta G, Weir MR, Friedewald JJ, Verbesey J, Cooper M, Segev DL, Massie AB. Self-Reported Incident Hypertension and Long-Term Kidney Function in Living Kidney Donors Compared with Healthy Nondonors. Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1493-1499. doi: 10.2215/CJN.04020419. Epub 2019 Sep 19.
Results Reference
result
PubMed Identifier
20634322
Citation
Davis CL, Cooper M. The state of U.S. living kidney donors. Clin J Am Soc Nephrol. 2010 Oct;5(10):1873-80. doi: 10.2215/CJN.01510210. Epub 2010 Jul 15.
Results Reference
result
PubMed Identifier
16880460
Citation
Boudville N, Prasad GV, Knoll G, Muirhead N, Thiessen-Philbrook H, Yang RC, Rosas-Arellano MP, Housawi A, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network. Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med. 2006 Aug 1;145(3):185-96. doi: 10.7326/0003-4819-145-3-200608010-00006.
Results Reference
result
PubMed Identifier
28742762
Citation
Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberu J, Bakr MA, Gallon L, Garvey CA, Guleria S, Li PK, Segev DL, Taler SJ, Tanabe K, Wright L, Zeier MG, Cheung M, Garg AX. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017 Aug;101(8S Suppl 1):S1-S109. doi: 10.1097/TP.0000000000001769.
Results Reference
result
PubMed Identifier
10450301
Citation
Svetkey LP, Sacks FM, Obarzanek E, Vollmer WM, Appel LJ, Lin PH, Karanja NM, Harsha DW, Bray GA, Aickin M, Proschan MA, Windhauser MM, Swain JF, McCarron PB, Rhodes DG, Laws RL. The DASH Diet, Sodium Intake and Blood Pressure Trial (DASH-sodium): rationale and design. DASH-Sodium Collaborative Research Group. J Am Diet Assoc. 1999 Aug;99(8 Suppl):S96-104. doi: 10.1016/s0002-8223(99)00423-x.
Results Reference
result
PubMed Identifier
26902492
Citation
Gay HC, Rao SG, Vaccarino V, Ali MK. Effects of Different Dietary Interventions on Blood Pressure: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 2016 Apr;67(4):733-9. doi: 10.1161/HYPERTENSIONAHA.115.06853. Epub 2016 Feb 22.
Results Reference
result
PubMed Identifier
29198468
Citation
Yoon CY, Noh J, Lee J, Kee YK, Seo C, Lee M, Cha MU, Kim H, Park S, Yun HR, Jung SY, Jhee JH, Han SH, Yoo TH, Kang SW, Park JT. High and low sodium intakes are associated with incident chronic kidney disease in patients with normal renal function and hypertension. Kidney Int. 2018 Apr;93(4):921-931. doi: 10.1016/j.kint.2017.09.016. Epub 2017 Dec 1.
Results Reference
result
PubMed Identifier
27218629
Citation
Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, Delafontaine P, Keane MG, Mohler E, Ojo A, Rahman M, Ricardo AC, Soliman EZ, Steigerwalt S, Townsend R, He J; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. JAMA. 2016 May 24-31;315(20):2200-10. doi: 10.1001/jama.2016.4447.
Results Reference
result
PubMed Identifier
27287605
Citation
Anjum S, Muzaale AD, Massie AB, Bae S, Luo X, Grams ME, Lentine KL, Garg AX, Segev DL. Patterns of End-Stage Renal Disease Caused by Diabetes, Hypertension, and Glomerulonephritis in Live Kidney Donors. Am J Transplant. 2016 Dec;16(12):3540-3547. doi: 10.1111/ajt.13917. Epub 2016 Jul 12.
Results Reference
result
PubMed Identifier
17995588
Citation
Lee JH, Kim SC, Han DJ, Chang JW, Yang WS, Park SK, Lee SK, Park JS, Kim SB. Risk factors for MDRD-GFR of less than 60 mL/min per 1.73 m2 in former kidney donors. Nephrology (Carlton). 2007 Dec;12(6):600-6. doi: 10.1111/j.1440-1797.2007.00852.x.
Results Reference
result
PubMed Identifier
24284516
Citation
Mjoen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Oyen O, Reisaeter A, Pfeffer P, Jenssen T, Leivestad T, Line PD, Ovrehus M, Dale DO, Pihlstrom H, Holme I, Dekker FW, Holdaas H. Long-term risks for kidney donors. Kidney Int. 2014 Jul;86(1):162-7. doi: 10.1038/ki.2013.460. Epub 2013 Nov 27.
Results Reference
result
PubMed Identifier
18671676
Citation
Young A, Storsley L, Garg AX, Treleaven D, Nguan CY, Cuerden MS, Karpinski M. Health outcomes for living kidney donors with isolated medical abnormalities: a systematic review. Am J Transplant. 2008 Sep;8(9):1878-90. doi: 10.1111/j.1600-6143.2008.02339.x. Epub 2008 Jul 28.
Results Reference
result
PubMed Identifier
11136953
Citation
Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001 Jan 4;344(1):3-10. doi: 10.1056/NEJM200101043440101.
Results Reference
result
PubMed Identifier
19414839
Citation
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006. Erratum In: Ann Intern Med. 2011 Sep 20;155(6):408.
Results Reference
result
PubMed Identifier
21796828
Citation
Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011. Available from http://www.ncbi.nlm.nih.gov/books/NBK56070/
Results Reference
result
PubMed Identifier
7791382
Citation
Low PA, Opfer-Gehrking TL, McPhee BR, Fealey RD, Benarroch EE, Willner CL, Suarez GA, Proper CJ, Felten JA, Huck CA, et al. Prospective evaluation of clinical characteristics of orthostatic hypotension. Mayo Clin Proc. 1995 Jul;70(7):617-22. doi: 10.4065/70.7.617.
Results Reference
result
PubMed Identifier
15611362
Citation
Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ; Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005 Jan;45(1):142-61. doi: 10.1161/01.HYP.0000150859.47929.8e. Epub 2004 Dec 20.
Results Reference
result
Citation
Cox DR. Regression models and life tables (with discussion). Journal of the Royal Statistical Society, Series B 34, 187-220, 1972.
Results Reference
result

Learn more about this trial

Dietary Sodium Intake and Blood Pressure in Living Kidney Donors

We'll reach out to this number within 24 hrs